A groundbreaking study demonstrates extended cardiac function improvement using platelet-derived growth factor-AB following myocardial infarction. The research, conducted in a clinically relevant porcine model, shows therapeutic benefits lasting 60 days post-treatment with comprehensive multi-modality assessment.
Breakthrough in Cardiac Regeneration
Researchers have demonstrated extended improvement in cardiac function using platelet-derived growth factor-AB (PDGF-AB) as a therapeutic agent for heart repair following myocardial infarction, according to a recent study published in npj Regenerative Medicine. The preclinical investigation, conducted in a porcine model that closely mimics human heart conditions, reportedly shows promising results for lasting cardiac recovery.